113 related articles for article (PubMed ID: 30228936)
1. Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.
Jørgensen MA; Holmström MO; Martinenaite E; Riley CH; Hasselbalch HC; Andersen MH
Oncoimmunology; 2018; 7(9):e1468957. PubMed ID: 30228936
[TBL] [Abstract][Full Text] [Related]
2. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Lorentzen CL; Martinenaite E; Kjeldsen JW; Holmstroem RB; Mørk SK; Pedersen AW; Ehrnrooth E; Andersen MH; Svane IM
Front Immunol; 2022; 13():1023023. PubMed ID: 36330525
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.
Holmström MO; Hasselbalch HC; Andersen MH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630667
[TBL] [Abstract][Full Text] [Related]
4. Frequent adaptive immune responses against arginase-1.
Martinenaite E; Mortensen REJ; Hansen M; Orebo Holmström M; Munir Ahmad S; Grønne Dahlager Jørgensen N; Met Ö; Donia M; Svane IM; Andersen MH
Oncoimmunology; 2018; 7(3):e1404215. PubMed ID: 29399404
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.
Holmström MO; Riley CH; Skov V; Svane IM; Hasselbalch HC; Andersen MH
Oncoimmunology; 2018; 7(6):e1433521. PubMed ID: 29872567
[TBL] [Abstract][Full Text] [Related]
6. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Martinenaite E; Ahmad SM; Bendtsen SK; Jørgensen MA; Weis-Banke SE; Svane IM; Andersen MH
Cancer Immunol Immunother; 2019 Nov; 68(11):1901-1907. PubMed ID: 31690955
[TBL] [Abstract][Full Text] [Related]
7. The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Weis-Banke SE; Hübbe ML; Holmström MO; Jørgensen MA; Bendtsen SK; Martinenaite E; Carretta M; Svane IM; Ødum N; Pedersen AW; Met Ö; Madsen DH; Andersen MH
Oncoimmunology; 2020 Jun; 9(1):1771142. PubMed ID: 32923127
[TBL] [Abstract][Full Text] [Related]
8. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I.
Liu Q; Zhang C; Sun A; Zheng Y; Wang L; Cao X
J Immunol; 2009 May; 182(10):6207-16. PubMed ID: 19414774
[TBL] [Abstract][Full Text] [Related]
9. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice.
Narita Y; Kitamura H; Wakita D; Sumida K; Masuko K; Terada S; Nakano K; Nishimura T
J Immunol; 2013 Jan; 190(2):812-20. PubMed ID: 23248265
[TBL] [Abstract][Full Text] [Related]
10. Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma.
Tate DJ; Vonderhaar DJ; Caldas YA; Metoyer T; Patterson JR; Aviles DH; Zea AH
J Hematol Oncol; 2008 Sep; 1():14. PubMed ID: 18817562
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion.
Leonard W; Dufait I; Schwarze JK; Law K; Engels B; Jiang H; Van den Berge D; Gevaert T; Storme G; Verovski V; Breckpot K; De Ridder M
Radiother Oncol; 2016 May; 119(2):291-9. PubMed ID: 26874542
[TBL] [Abstract][Full Text] [Related]
12. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.
Zea AH; Rodriguez PC; Atkins MB; Hernandez C; Signoretti S; Zabaleta J; McDermott D; Quiceno D; Youmans A; O'Neill A; Mier J; Ochoa AC
Cancer Res; 2005 Apr; 65(8):3044-8. PubMed ID: 15833831
[TBL] [Abstract][Full Text] [Related]
13. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.
Quandt J; Schlude C; Bartoschek M; Will R; Cid-Arregui A; Schölch S; Reissfelder C; Weitz J; Schneider M; Wiemann S; Momburg F; Beckhove P
Oncoimmunology; 2018; 7(12):e1500671. PubMed ID: 30524892
[TBL] [Abstract][Full Text] [Related]
14. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
15. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells Mediate Immunosuppression After Cardiopulmonary Bypass.
Hübner M; Tomasi R; Effinger D; Wu T; Klein G; Bender M; Kilger E; Juchem G; Schwedhelm E; Kreth S
Crit Care Med; 2019 Aug; 47(8):e700-e709. PubMed ID: 31149961
[TBL] [Abstract][Full Text] [Related]
17. Arginase I expression and activity in human mononuclear cells after injury.
Ochoa JB; Bernard AC; O'Brien WE; Griffen MM; Maley ME; Rockich AK; Tsuei BJ; Boulanger BR; Kearney PA; Morris SM
Ann Surg; 2001 Mar; 233(3):393-9. PubMed ID: 11224628
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
[TBL] [Abstract][Full Text] [Related]
19. Myeloid-Derived Suppressor Cells Contribute to Susceptibility to
Onyilagha C; Kuriakose S; Ikeogu N; Jia P; Uzonna J
J Immunol; 2018 Jul; 201(2):507-515. PubMed ID: 29898961
[TBL] [Abstract][Full Text] [Related]
20. Cancer immune therapy for myeloid malignancies: present and future.
Holmström MO; Hasselbalch HC
Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
